MAINTAINING J&J'S MOMENTUM - CEO William Weldon has a daunting challenge: Keeping the Johnson & Johnson juggernaut on course. For the past two decades, the health-care company posted double-digit earnings growth without fail. But with sales of (USD)36 billion, the once-reliable method of snapping up other companies barely budges the bottom line. And most or J&J's drugs are under competitive ...
|Year of Publication:||
|Type of Publication:||Article|
|Title record from database:|| OLC-SSG Economic Sciences|
|Availability:||More access options|
|More options (other):|
|Description not available.|